Selected article for: "acute infection and admission course"
Author: Eşkazan, Ahmet Emre; Balkan, İlker İnanç; Demirbaş, Kaan Can; Ar, Muhlis Cem; Karaali, Rıdvan; Sekibağ, Yonca; Mulamahmutoğlu, Sait; Dumanlı, Güleren Yartaş; Çakmak, Fatih; Yurttaş, Nurgül Özgür; Kurt, Furkan; Kurt, Seda Aladağ; Kuşkucu, Mert; Ürkmez, Seval; Börekçi, Şermin; Saribal, Devrim; Mete, Bilgül; Bavunoğlu, Işıl; Dikmen, Yalım; Aygün, Gökhan; Midilli, Kenan; Tabak, Fehmi
Title: Tocilizumab in COVID-19: the CerrahpaÅŸa-PREDICT score
  • Cord-id: zadpy3s8
  • Document date: 2021_5_12
    • ID: zadpy3s8
    Snippet: Background Cytokine release syndrome (CRS), characterized by overproduction of proinflammatory cytokines in the course of severe coronavirus disease 2019 (COVID-19), has been suggested as the major cause of mortality. Tocilizumab, a recombinant humanized monoclonal antibody against human IL-6 receptor, poses a therapeutic option for the treatment of CRS leading to severe acute respiratory syndrome in coronavirus-2 (SARS-CoV-2) infection. Methods We performed a single-center retrospective study t
    Document: Background Cytokine release syndrome (CRS), characterized by overproduction of proinflammatory cytokines in the course of severe coronavirus disease 2019 (COVID-19), has been suggested as the major cause of mortality. Tocilizumab, a recombinant humanized monoclonal antibody against human IL-6 receptor, poses a therapeutic option for the treatment of CRS leading to severe acute respiratory syndrome in coronavirus-2 (SARS-CoV-2) infection. Methods We performed a single-center retrospective study to reveal the outcome of COVID-19 patients on tocilizumab and proposed “the Cerrahpaşa-PREDICT score”, a new clinical scoring system using clinical and laboratory parameters that would help predicting the 28-day mortality of COVID-19 patients receiving tocilizumab. Results Eighty-seven patients (median age: 59 years) were included of whom 75.8% were male. Tocilizumab use significantly improved clinical and laboratory parameters. The 28-day mortality rate on tocilizumab was 16.1%. The Cerrahpaşa-PREDICT score, consisting of platelet counts, procalcitonin, D-dimer levels, SO2R and the time from symptom onset to tocilizumab administration had a positive predictive value of 94.5% and negative predictive value of 92.9% for anticipating 28-day mortality. Conclusions Severe COVID-19 should closely be monitored for the signs of hyperinflammation. We showed that administration of tocilizumab early in the course of the disease (prior to ICU admission) resulted in a favorable outcome. Close monitoring usually aids identifying patients who would benefit from tocilizumab. In this regard, the Cerrahpaşa-PREDICT score might serve as a practical tool for estimating the 28-day mortality in COVID-19 patients who received tocilizumab and would facilitate timely recognition of fatal cases to be evaluated for other therapeutic options.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and admission nlr: 1, 2, 3, 4, 5
    • acute respiratory syndrome and admission parameter: 1, 2, 3
    • acute respiratory syndrome and admission significantly high: 1, 2
    • acute respiratory syndrome and admission symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory syndrome and admission symptom onset median time: 1, 2, 3, 4, 5
    • acute respiratory syndrome and load measurement: 1, 2, 3, 4
    • acute respiratory syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and logistic regression analysis multivariate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute severe pneumonia and admission high: 1, 2, 3, 4
    • acute severe pneumonia and admission symptom onset: 1, 2
    • acute severe pneumonia and admission symptom onset median time: 1
    • acute severe pneumonia and logistic regression: 1, 2, 3, 4, 5, 6
    • acute severe pneumonia and logistic regression analysis: 1
    • acute severe pneumonia and logistic regression model: 1, 2
    • admission high and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission high and logistic regression analysis multivariate: 1, 2, 3, 4, 5, 6, 7, 8
    • admission high and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8